论文部分内容阅读
应用美国产ACL200型自动凝血仪检侧34例肝硬化患者及30例健康人。结果提示:PT、APTT明显延长,与健康人相比有显著差异(P<0,01)FIB明显减少,与对照组相比有显著差异(P<0.01)。凝血因子活性(Ⅱ、Ⅴ、Ⅶ、Ⅸ、Ⅹ)明显降低,与健康人相比有显著差异(P<0.01)。对肝硬化进行凝血因子的检侧,有助于早期发现肝病时凝血机制障碍,对肝硬化患者的愈后及出血的治疗有重要意义。
Application of the United States produced ACL200 automatic coagulation device 34 patients with cirrhosis and 30 healthy people. The results showed that PT and APTT were significantly prolonged, and there was a significant difference (P <0,01) compared with healthy people. FIB significantly decreased compared with the control group (P <0.01). The activity of coagulation factors (Ⅱ, Ⅴ, Ⅶ, Ⅸ, Ⅹ) was significantly lower than that of healthy people (P <0.01). Detection of clotting factor in cirrhosis of liver cirrhosis helps to find out the obstacles of coagulation mechanism in the early stage of liver disease and is of great significance to the treatment of patients with liver cirrhosis and hemorrhage.